Brain Iron Levels as Potential Indicator for Alzheimer’s Disease

New research indicates that elevated brain iron levels may signal an increased risk of developing Alzheimer’s disease in the future.

High concentrations of certain elements can amplify cerebral toxins and lead to neurodegeneration, which often contributes to cognitive decline. This effect is especially pronounced when these elements interact with abnormal amyloid and tau proteins—both of which are characteristic of Alzheimer’s.

Researchers from Johns Hopkins University have employed a specialized MRI method known as quantitative sensitivity mapping (QSM) to measure iron levels in the brain.

“QSM, a sophisticated MRI technique developed in the past decade, is designed to accurately assess magnetic sensitivity in tissues,” explained Xu Li, an associate professor of radiology at Johns Hopkins. “It identifies subtle differences in iron concentrations across various brain regions, providing a reliable non-invasive way to quantify iron that traditional MRI methods cannot achieve.”

When compared to other diagnostic imaging techniques, such as PET scans for Alzheimer’s, QSM MRI is noted to be both non-invasive and more cost-effective.

This method could help forecast potential mild cognitive impairment (MCI) and cognitive decline, even in individuals who haven’t yet exhibited symptoms.

In the study, published in Journal Radiology, researchers evaluated MRI techniques in 158 cognitively intact contributors from previous studies.

After following these individuals for seven and a half years, the team found that higher iron levels in two critical brain regions correlated with an increased risk of mild cognitive impairment—a common precursor to Alzheimer’s.

“Our study shows that higher iron levels are linked to a two to four times greater risk of MCI and cognitive decline, particularly in key areas associated with memory and learning,” Li shared.

Li further noted that such alterations in brain iron levels might be detectable years before any significant memory loss manifests.

“We’ve used QSM to identify heightened brain iron in memory-related regions, which correlates with an increased risk of cognitive impairment and accelerated cognitive decline, especially among those with elevated amyloid pathology,” he added.

The study does have its limitations, with Li mentioning that the sample size was relatively small. “The participants were drawn from a specialized group, predominantly white, highly educated individuals with a notable family history of Alzheimer’s,” the researchers acknowledged.

Follow-up studies involving larger and more diverse groups are needed to validate these findings, as noted in the release.

“I believe there is hope,” Li commented. “Tools like this could assist in identifying individuals at high risk for Alzheimer’s, paving the way for early interventions as new treatments become accessible. Beyond serving as a biomarker, iron may also emerge as a potential therapeutic target.”

Looking ahead, researchers hope that QSM technology will become more standardized and widely available.

Li pointed out that while brain iron is often linked to neurodegeneration and rapid cognitive decline, it also plays an essential role in cognitive health and development during younger years.

“Iron chelation therapy is currently under investigation for Alzheimer’s, but its effectiveness remains unclear and warrants further research,” he concluded.

This study received support from the National Institute of Biomedical Imaging and Bioengineering, the National Institutes of Aging, and the National Institutes of Health.